The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women
Open Access
- 12 February 2005
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (11) , 1368-1374
Abstract
Regulation of osteoclastic activity is critical for understanding bone loss associated with the postmenopausal period. In vitro and animal studies have revealed the role of OPG as a decoy receptor that neutralizes the effect of RANKL on the differentiation and activation of osteoclasts. However, the role of the OPG-RANKL system in postmenopausal osteoporosis is controversial. Thus, the aim of this study was to investigate the relationship among circulating levels of OPG, RANKL, bone turnover markers (BTM), bone mineral density (BMD) and vertebral fractures in postmenopausal women. We determined anthropometric parameters, circulating OPG and RANKL, BTM, estradiol, BMD by dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN), and pre-existing vertebral fractures in 206 ambulatory postmenopausal women of a mean age of 62 years (SD 7). Circulating OPG was significantly related to age ( r =0.158; P =0.023), years since menopause ( r =0.167; P =0.016) and BMD (LS Z-score: r =0.240; P =0.001, FN Z-score: r =0.156; P =0.025). Over half of the women had undetectable RANKL ( n =113; 54.9%). There were no significant differences in clinical variables, BTM or BMD among women with detectable vs. undetectable RANKL. OPG was found to be independently associated with osteoporosis (OR: 2.9, 1.4–5.9) and prevalent vertebral fractures (OR: 2.5, 1.2–5.4). We conclude that serum OPG levels are independently associated with bone mass and prevalent vertebral fractures in postmenopausal women.Keywords
This publication has 30 references indexed in Scilit:
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2004
- Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels.Osteoporosis International, 2003
- High serum osteoprotegerin and low RANKL in primary biliary cirrhosisJournal of Hepatology, 2003
- Decreased Bone Density, Elevated Serum Osteoprotegerin, and β-Cross-Laps in Wilson DiseaseJournal of Bone and Mineral Research, 2002
- Correlates of Osteoprotegerin Levels in Women and MenOsteoporosis International, 2002
- The Effect of a Single Dose of Osteoprotegerin in Postmenopausal WomenJournal of Bone and Mineral Research, 2001
- Differences in Skeletal Kinetics Between Vertebral and Humeral Bone Measured by 18F-Fluoride Positron Emission Tomography in Postmenopausal WomenJournal of Bone and Mineral Research, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 1999
- The influence of alcohol consumption on the risk of vertebral deformityOsteoporosis International, 1997